Titration of Variant HSV1-tk Gene Expression to Determine the Sensitivity of 18F-FHBG PET Imaging in a Prostate Tumor

被引:8
作者
Johnson, Mai [1 ,2 ]
Karanikolas, Breanne D. W. [1 ]
Priceman, Saul J. [1 ]
Powell, Russell [1 ]
Black, Margaret E. [3 ]
Wu, Hsiao-Ming [1 ]
Czernin, Johannes [1 ]
Huang, Sung-Cheng [1 ]
Wu, Lily [1 ,2 ]
机构
[1] Univ Calif Los Angeles, Dept Mol & Medicalacol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Dept Mol Cellular & Integrat Physiol, Los Angeles, CA 90095 USA
[3] Washington State Univ, Dept Pharmaceut Sci, Pullman, WA 99164 USA
关键词
prostate cancer; thymidine kinase; PET; transgene expression; lentivirus; POSITRON-EMISSION-TOMOGRAPHY; HSV-TK GENE; REPORTER GENE; IN-VIVO; SUICIDE GENE; TRANSGENE EXPRESSION; CANCER; THERAPY; CELLS; ADENOVIRUS;
D O I
10.2967/jnumed.108.058438
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Because of its high selectivity and specificity for the imaging reporter probe 9-(4-F-18-fluoro-3-[hydroxymethyl] butyl) guanine (F-18-FHBG), the herpes simplex virus type 1 thymidine kinase (HSV1-tk) variant sr39tk is actively being studied as a PET reporter gene. We recently demonstrated the capability of using a prostate-specific transcriptional amplification PET reporter vector, AdTSTA-sr39tk, to target prostate cancer lymph node metastasis. However, one area that warrants further study is the examination of the sensitivity of PET by determining the minimum percentage of cells expressing the sr39tk transgene needed for detection. Addressing this question could determine the sensitivity of vector-mediated sr39tk PET in cancer-targeting strategies. Methods: DU-145, PC-3, and CWR22Rv.1 prostate cancer cell lines (a total of 1 x 10(6) cells) were studied, of which 7%, 10%, 25%, 50%, or 70% were transduced with the lentiviral vector constitutively expressing HSV1-sr39tk-IRES-enhanced green fluorescent protein (EGFP). Cells were subcutaneously implanted into the left shoulder of severe combined immunodeficient mice and evaluated. Tumor cells comparably transduced with an EGFP control vector were implanted on the right shoulder. Mice were imaged using PET with F-18-FHBG at 8, 15, and 22 d after tumor implant. On day 23, tumors were isolated and analyzed for sr39tk transgene expression by quantitative reverse-transcriptase polymerase chain reaction (RT-PCR), Western blotting, immunohistochemistry, and flow cytometry for EGFP expression. Results: Results showed a linear relationship between the level of sr39tk expression and the quantity of tracer accrual in DU-145, with the minimal value for PET detection at 10%. The magnitude of tracer retention in sr39tk-expressing cells was amplified over time as the tumor grew. Protein levels in the stepwise titration increased with the percentage of sr39tk-transduced cells. Conclusion: The stepwise titration of prostate cancer cells transduced with the lenti-CMV-sr39tk-IRES-EGFP determined the minimum number of sr39tk-expressing tumor cells necessary to be detected by PET using the F-18-FHBG reporter probe. Furthermore, PET signal correlated well with traditional methods of protein evaluation such as flow cytometry, quantitative RT-PCR, Western blotting, and immunohistochemistry. Unlike the traditional methods, however, the use of PET is noninvasive and will be more advantageous in clinical situations.
引用
收藏
页码:757 / 764
页数:8
相关论文
共 41 条
  • [21] Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene
    Miletic, Hrvoje
    Fischer, Yvonne
    Litwak, Sara
    Giroglou, Tsanan
    Waerzeggers, Yannic
    Winkeler, Alexandra
    Li, Huongfeng
    Himmelreich, Uwe
    Lange, Claudia
    Stenzel, Werner
    Deckert, Martina
    Neumann, Harald
    Jacobs, Andreas H.
    von Laer, Dorothee
    [J]. MOLECULAR THERAPY, 2007, 15 (07) : 1373 - 1381
  • [22] Comparison of [18F]FHBG and [14C]FIAU for imaging of HSV1-tk reporter gene expression:: adenoviral infection vs stable transfection
    Min, JJ
    Iyer, M
    Gambhir, SS
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (11) : 1547 - 1560
  • [23] Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy
    Nasu, Yasutomo
    Saika, Takashi
    Ebara, Shin
    Kusaka, Nobuyuki
    Kaku, Haruki
    Abarzua, Fernando
    Manabe, Daisuke
    Thompson, Timothy C.
    Kumon, Hiromi
    [J]. MOLECULAR THERAPY, 2007, 15 (04) : 834 - 840
  • [24] Biodistribution, PET, and radiation dosimetry estimates of HSV-tk gene expression imaging agent 1-(2′-deoxy-2′-18F-fluoro-β-D-arabinofuranosyl)-5-iodouracil in normal dogs
    Nimmagadda, Sridhar
    Mangner, Thomas J.
    Douglas, Kirk A.
    Muzik, Otto
    Shields, Anthony F.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2007, 48 (04) : 655 - 660
  • [25] Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients
    Peñuelas, I
    Mazzolini, G
    Boán, JF
    Sangro, B
    Martí-Climent, JP
    Ruiz, M
    Ruiz, J
    Satyamurthy, N
    Qian, C
    Barrio, JR
    Phelps, ME
    Richter, JA
    Gambhir, SS
    Prieto, J
    [J]. GASTROENTEROLOGY, 2005, 128 (07) : 1787 - 1795
  • [26] Imaging the spatial distribution of transgene expression in the lungs with positron emission tomography
    Richard, JC
    Factor, P
    Welch, LC
    Schuster, DP
    [J]. GENE THERAPY, 2003, 10 (25) : 2074 - 2080
  • [27] Rogers BE, 2005, J NUCL MED, V46, P1889
  • [28] Sander WE, 2006, J NUCL MED, V47, P1212
  • [29] Configurations of a two-tiered amplified gene expression system in adenoviral vectors designed to improve the specificity of in vivo prostate cancer imaging
    Sato, M.
    Figueiredo, M. L.
    Burton, J. B.
    Johnson, M.
    Chen, M.
    Powell, R.
    Gambhir, S. S.
    Carey, M.
    Wu, L.
    [J]. GENE THERAPY, 2008, 15 (08) : 583 - 593
  • [30] Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer
    Shirakawa, Toshiro
    Terao, Shuji
    Hinata, Nobuyuki
    Tanaka, Kazushi
    Takenaka, Atsushi
    Hara, Isao
    Sugimura, Kazuro
    Matsuo, Masafumi
    Hamada, Katsuyuki
    Fuji, Kohzo
    Okegawa, Takatsugu
    Higashihara, Eiji
    Gardner, Thomas A.
    Kao, Chinghai
    Chung, Leland W. K.
    Kamidono, Sadao
    Fujisawa, Masato
    Gotoh, Akinobu
    [J]. HUMAN GENE THERAPY, 2007, 18 (12) : 1225 - 1232